Analyst Ratings February 20, 2026

Piper Sandler Lowers Weave Communications Price Target as Growth Outlook Softens

Analyst trims target to $8, cites decelerating revenue growth despite payments strength and specialty medical traction

By Jordan Park WEAV
Piper Sandler Lowers Weave Communications Price Target as Growth Outlook Softens
WEAV

Piper Sandler reduced its price objective on Weave Communications Inc to $8 from $12 while keeping an Overweight rating, reflecting a more cautious view on near-term growth. The company reported back-to-back quarters of 17% year-over-year revenue growth, powered by payments expansion and specialty medical location gains, but guided to slower top-line growth in fiscal 2026. Piper Sandler and other analysts flagged AI product rollouts and the specialty medical vertical as key drivers for the year ahead.

Key Points

  • Piper Sandler reduced Weave Communications price target to $8 from $12 while keeping an Overweight rating.
  • Weave reported two consecutive quarters of 17% year-over-year revenue growth, with payments up an estimated 35% year-over-year and record specialty medical location additions.
  • Fiscal 2026 guidance calls for 14.8% top-line growth and about 190 basis points of operating margin expansion; AI products and the specialty medical vertical are expected to be the main growth drivers.

Piper Sandler on Thursday moved down its 12-month price target for Weave Communications Inc (NYSE:WEAV) to $8 from $12, while leaving its Overweight recommendation in place.

The firm’s adjustment comes amid mixed operational signals from the communications and payments platform. Weave reported its second straight quarter of 17% year-over-year revenue growth. Management attributed that performance to several factors: payments growth estimated at 35% year-over-year, record quarterly location additions within the specialty medical vertical, and the contribution from the recently completed TrueLark acquisition.

Even with those drivers, the stock has underperformed. Shares traded at $5.74, implying a market capitalization of $445 million, and have fallen 66% over the past year.

Looking ahead, Weave provided fiscal 2026 guidance for top-line growth of 14.8% year-over-year, a pace that is roughly in line with consensus expectations but represents a deceleration from the 17% growth achieved in fiscal 2025. The company’s operating income guidance points to roughly 190 basis points of operating margin expansion in the coming year.

InvestingPro analysis referenced in the company update indicates the stock is currently undervalued, and analysts expect the company to move to profitability this year. A cited 72% gross profit margin is described as a supporting factor in that transition.

Piper Sandler identified two primary growth levers for fiscal 2026: AI-enabled products and continued expansion in the specialty medical vertical. The firm expects an AI omnichannel receptionist product to reach general availability in the first half of 2026, with AI offerings beginning to influence top-line growth in the second half of the year. The specialty medical segment is noted as Weave’s fastest growing area; the company has initially targeted four of 29 total sub-verticals within that broader category.


In separate coverage, Raymond James downgraded EverCommerce Inc from Outperform to Market Perform, citing valuation concerns after the stock significantly outperformed peers. EverCommerce shares gained 15% over the past six months and 10% over the past year. By comparison, the iShares Expanded Tech-Software Sector ETF fell 2% over six months and rose 6% over the past year. Raymond James noted there were no recent earnings or revenue results, and no mergers or acquisitions were announced in conjunction with the downgrade. No additional major company news was highlighted in the firm’s update.

Taken together, the analyst actions reflect a market balancing near-term execution and product timing against expectations for margin improvement and future revenue contributions from AI and specialty medical initiatives.

Risks

  • Top-line deceleration: Guidance for fiscal 2026 implies a slowdown from fiscal 2025 growth rates, which could affect software and payments sector sentiment.
  • Timing of AI product impact: Piper Sandler anticipates AI offerings will affect revenue in the second half of 2026, so delayed availability or adoption could postpone expected top-line contributions for the tech and healthcare software markets.
  • Valuation concerns for outperformed names: Raymond James downgraded EverCommerce due to significant recent stock outperformance, underlining market sensitivity to valuation in the software sector.

More from Analyst Ratings

BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026 Supreme Court Ruling Boosts Steve Madden Outlook, Analysts Say Feb 20, 2026 UBS Lowers Carvana Price Target Citing Higher Costs, Keeps Buy Rating Feb 20, 2026 UBS Lifts Cheesecake Factory Price Target as Margins Improve, Keeps Sell Rating Feb 20, 2026